Citizens Jmp Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citizens Jmp from $102.00 to $112.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would indicate a potential upside of 21.63% from the company’s previous close.

Several other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Citigroup increased their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Truist Financial lifted their price target on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a report on Monday, January 5th. Weiss Ratings downgraded shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, February 17th. Finally, Jefferies Financial Group increased their price objective on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.31.

Protagonist Therapeutics Price Performance

Shares of NASDAQ PTGX opened at $92.08 on Thursday. The company has a 50-day simple moving average of $84.24 and a 200-day simple moving average of $76.86. The company has a market cap of $5.88 billion, a PE ratio of -44.92 and a beta of 2.26. Protagonist Therapeutics has a 12 month low of $35.97 and a 12 month high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The firm had revenue of $7.44 million for the quarter, compared to analysts’ expectations of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.50%. On average, analysts anticipate that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insider Buying and Selling

In other news, Director Lewis T. Williams sold 18,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total value of $1,483,560.00. Following the transaction, the director directly owned 7,825 shares of the company’s stock, valued at $644,936.50. The trade was a 69.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Arturo Md Molina sold 13,151 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $82.42, for a total value of $1,083,905.42. Following the sale, the insider owned 84,115 shares of the company’s stock, valued at $6,932,758.30. The trade was a 13.52% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 203,167 shares of company stock worth $16,889,199. Corporate insiders own 4.90% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

A number of hedge funds have recently made changes to their positions in PTGX. Farther Finance Advisors LLC lifted its holdings in shares of Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after acquiring an additional 156 shares in the last quarter. Greenline Wealth Management LLC acquired a new stake in Protagonist Therapeutics in the 4th quarter valued at $27,000. Bessemer Group Inc. raised its position in Protagonist Therapeutics by 171.0% in the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after purchasing an additional 318 shares during the period. Salomon & Ludwin LLC purchased a new position in Protagonist Therapeutics in the third quarter valued at about $29,000. Finally, CWM LLC lifted its stake in shares of Protagonist Therapeutics by 201.5% during the second quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after purchasing an additional 407 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

More Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Barclays raised its price target on PTGX from $108 to $113 and maintained an “overweight” rating — a sizable upside signal from a major bank that supports continued buying interest. Article Title
• Positive Sentiment: Citizens JMP bumped its target from $102 to $112 with a “market outperform” call, reinforcing bullish analyst sentiment and adding short-term demand pressure. Article Title
• Positive Sentiment: TD Cowen raised its price target from $90 to $100 and kept a “buy” stance — another price-target lift that supports upward momentum. Article Title
• Positive Sentiment: HC Wainwright materially raised its FY2026 EPS view (to $4.18 from $3.40) and sharply lifted Q3 2026 EPS to $3.60 (from $0.05), while reiterating a “Buy” rating and a $117 target — a near-term earnings upgrade that investors may view as validation of upcoming revenue/catalyst expectations.
• Neutral Sentiment: Coverage roundup: a Benzinga piece summarizes analyst views across eight firms, useful for context but not a direct catalyst. A Glimpse Into The Expert Outlook
• Negative Sentiment: HC Wainwright also cut several longer-term and quarter-specific estimates: Q4 2026 EPS was lowered sharply to ($0.71) from $2.04, FY2027 and FY2028 forecasts were reduced (to -$2.06 and -$2.08 respectively), and FY2029/FY2030 targets were trimmed dramatically — signaling greater model uncertainty and potential volatility in multi-year expectations.
• Negative Sentiment: Smaller cuts: HC Wainwright nudged Q2 2026 EPS down to $1.98 from $2.03 and trimmed FY2029/FY2030 estimates significantly — these revisions highlight sensitivity in the firm’s forecasting and could temper enthusiasm if investors focus on the downgraded out-years.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.